ABSTRACT
Introducción: el déficit de atención con hiperactividad (TDAH) es un trastorno neuropsiquiátrico común en la infancia y en la adolescencia. Sin embargo, existen pocos estudios que muestren la situación actual de este trastorno desde la perspectiva del pediatra de Atención Primaria. Material y métodos: a fecha de 1 de julio de 2011, fueron seleccionados los pacientes de edad comprendida entre 6 y 14 años de edad controlados en el centro de salud de Catarroja que presentaban el diagnóstico de TDAH. A partir de la historia clínica se procedió a la recogida de datos del paciente, de los profesionales involucrados en el diagnóstico, del tratamiento y del seguimiento. Resultados: de los 2466 niños entre 6 y 14 años de edad registrados, 47 estaban diagnosticados de TDAH (1,9%). La mayoría de los pacientes fueron remitidos desde Pediatría de Atención Primaria para ser estudiados por Neuropediatría y/o Psiquiatría infantil. El tratamiento más extendido fue el metilfenidato (87%), seguido de atomoxetina (4%). Se realizaron exploraciones complementarias al 32% de los pacientes durante el seguimiento, para descartar otras causas de los síntomas. La existencia de comorbilidades asociadas fue similar a la encontrada en otros estudios. La evolución fue favorable en la mayoría de los pacientes en los que se registró la evolución (36%). Conclusión: la prevalencia de TDAH encontrada en nuestra área ha sido baja, probablemente debido al diseño del estudio. Los pacientes son diagnosticados y tratados mayoritariamente por las especialidades de Neuropediatría y/o Psiquiatría infantil. Algunos de los pacientes son tratados por el pediatra de cabecera, tendencia que esperamos siga en aumento(AU)
Introduction: ATtention Deficit Hyperactivity Disorder (ADHD) is a common neurobehavioral disorder in children and adolescents. However there are not studies about this condition from the standpoint of the primary care pediatrician. Material and methods: on July 2011 the patients with the diagnosis of AHDH and between 6 to 12 years of age were selected at the Catarroja Health Center (Valencia). Patient data from the clinical history were recorded and who was the professional that made the diagnosis, treatment and follow up. Results: forty-seven children were diagnosed of ADHD from a total of 2466 (prevalence rate 1.9%). Most of them were referred from the primary care pediatrician to the pediatric neurologist of psychiatrist. The most common treatment was methylphenidate followed by atomexetine. Complementary test were performed in 32% of the patients to rule out alternative causes for the symptoms. The coexisting conditions found were similar to other reports. The outcome of the patients, when reporte, was satisfactory in most of them (36%). Conclusion: the prevalence found in our area is low, probably due to the study design. PAtients are diagnosed and treated frequently by the pediatric neurologist or psychiatrist. Some of the cases are treated by the pediatrician, tendency that we hope to be increased(AU)
Subject(s)
Humans , Male , Female , Child , Adolescent , Attention Deficit Disorder with Hyperactivity/epidemiology , Attention Deficit Disorder with Hyperactivity/prevention & control , Attention Deficit and Disruptive Behavior Disorders/complications , Primary Health Care/methods , Primary Health Care/trends , Neurophysiology/methods , Primary Health Care/organization & administration , Primary Health Care , Neuropsychiatry/methods , Neuropsychiatry/trends , Data Collection/methods , Data Collection , Child Psychiatry/methods , Child Psychiatry/trends , Medical Records/statistics & numerical data , ComorbidityABSTRACT
Objetivo: Determinar la utilidad de la insulina glargina (IG) en la disminución de hipoglucemias e hiperglucemias en niños y adolescentes con diabetes tipo 1. Pacientes y métodos: Se trata de un estudio retrospectivo/prospectivo, en el que 29 pacientes con hipoglucemias leves/moderadas frecuentes, con edades comprendidas entre 3 y 18 años, y HbA1c de 8 ± 0,7, recibieron tratamiento con IG una vez al día e insulina regular o un análogo de la insulina rápida antes de cada comida. Los criterios de inclusión fueron los siguientes: a) tratamiento previo con insulina de acción intermedia (NPH); b) más de 1 año de evolución de la diabetes, y c) más de tres controles de glucemia/día. Se recogió la incidencia de episodios de hipoglucemias (leves, moderadas y graves), hiperglucemias, los valores de HbA1c, el índice de masa corporal y la dosis diaria de insulina antes y después de iniciar el tratamiento con IG. Además, se realiza una encuesta de opinión directa a la familia sobre la calidad de vida. Resultados: Los resultados se obtuvieron a partir de 1.294 ± 411 glucemias/paciente. La incidencia global de hipoglucemias no se reduce (el 5,9 frente al 6,2 % de valores glucémicos/mes) y las hiperglucemias globales permanecen sin cambios. Sin embargo, se reduce de forma significativa la hiperglucemia en ayunas (el 4,3 frente al 2,6 %) con tendencia a la disminución de las hipoglucemias nocturnas. La HbA1c continúa también sin cambios al igual que los requerimientos totales de insulina diaria (0,8 ± 0,2 U/kg/día). Conclusiones: La IG consigue un control glucémico similar al que se logra con la NPH, con tendencia a la disminución de las hipoglucemias nocturnas y a la mejoría de los valores de glucemia en ayunas (AU)
Objective: To determine the usefulness of insulin glargine (IG) to reduce hipoglycaemias and hyperglycaemic events in children and adolescents with type 1 diabetes. Patients and methods: In a retrospective/prospective study, 29 patients with a high number of non-severe hypoglycaemias, aged 3-18, and an average HbA1c of 8 ± 0.7, received IG once daily plus regular insulin or rapid analogue before meals. Inclusion criteria were: a) previous treatment with NPH insulin; b) diagnosis of type 1 diabetes for at least 1 year before starting IG, and c) > 3 blood glucose controls within a day. Incidence of severe and non-severe hypoglycaemic events, hyperglycaemic events, HbA1c values, body mass index, daily insulin dose before and after the institution of glargine therapy, were collected. Additionally, family were asked to complete a diabetes quality of life survey. Results: 1,294 ± 411 glycaemias/subject were obtained. Hypoglycaemic episodes were not reduced (5.9 % vs 6.2 %) and hyperglycaemic events remained unchanged. Fasting blood glucose levels decreased from 195.3 ± 36.6 to 162.8 ± 25.8 in all patients (p < 0.05) and a tendency a decrease in nocturnal hypoglycaemias was observed. The average HbA1c and total daily insulin dosis also remained unchanged (0.8 ± 0.2 UI/Kg/day). Conclusions: Using IG achieves a glycaemic control similar to NPH, with a tendency to decrease the frecuency of nocturnal hypoglycaemias and an improvement in fasting glycaemia values(AU)
Subject(s)
Humans , Male , Female , Child , Adolescent , Diabetes Mellitus, Type 1/diagnosis , Diabetes Mellitus, Type 1/therapy , Insulin/therapeutic use , Hyperglycemia/drug therapy , Hypoglycemia/drug therapy , Hypoglycemia/metabolism , Quality of Life , Body Mass Index , Retrospective Studies , Prospective StudiesABSTRACT
OBJECTIVE: To determine the usefulness of insulin glargine (IG) to reduce hipoglycaemias and hyperglycaemic events in children and adolescents with type 1 diabetes. PATIENTS AND METHODS: In a retrospective/prospective study, 29 patients with a high number of non-severe hypoglycaemias, aged 3-18, and an average HbA1c of 8+/-0.7, received IG once daily plus regular insulin or rapid analogue before meals. Inclusion criteria were: a) previous treatment with NPH insulin; b) diagnosis of type 1 diabetes for at least 1 year before starting IG, and c) >3 blood glucose controls within a day. Incidence of severe and non-severe hypoglycaemic events, hyperglycaemic events, HbA1c values, body mass index, daily insulin dose before and after the institution of glargine therapy, were collected. Additionally, family were asked to complete a diabetes quality of life survey. RESULTS: 1,294+/-411 glycaemias/subject were obtained. Hypoglycaemic episodes were not reduced (5.9% vs 6.2%) and hyperglycaemic events remained unchanged. Fasting blood glucose levels decreased from 195.3+/-36.6 to 162.8+/-25.8 in all patients (p<0.05) and a tendency a decrease in nocturnal hypoglycaemias was observed. The average HbA1c and total daily insulin doses also remained unchanged (0.8+/-0.2 UI/Kg/day). CONCLUSIONS: Using IG achieves a glycaemic control similar to NPH, with a tendency to decrease the frequency of nocturnal hypoglycaemias and an improvement in fasting glycaemia values.
